1,3-Bis(2-aminobenzimidazol-1-yl)benzene

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1,3-Bis(2-aminobenzimidazol-1-yl)benzene
• 英文别名: 1-[3-(2-aminobenzimidazol-1-yl)phenyl]benzimidazol-2-amine
• 化学式: C₂₀H₁₆N₆
• 分子量: 340.387
• InChiKey: KIURSVXHJPWENT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  87.7
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Potassium channel blocking agents
  申请人：NeuroSearch A/S

  公开号：US20020049246A1

  公开（公告）日：2002-04-25

  This invention relates to novel potassium channel blocking agents, and their use in the preparation of pharmaceutical compositions. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels, in particular asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel syndrome, gastrointestinal dysfunction, secretory diarrhoea, ischaemia, cerebral ischaemia, ischaemic hearth disease, angina pectoris, coronary hearth disease, traumatic brain injury, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, migraine, arrhythmia, hypertension, absence seizures, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression.

  本发明涉及新型钾通道阻滞剂及其在制备药物组合物中的应用。此外，本发明还涉及用于治疗或缓解与钾通道活性有关的疾病或疾病的药物组合物，特别是哮喘、囊性纤维化、慢性阻塞性肺疾病和流涕、惊厥、血管痉挛、冠状动脉痉挛、肾脏疾病、多囊肾病、膀胱痉挛、尿失禁、膀胱出流道梗阻、肠易激综合征、胃肠功能障碍、分泌性腹泻、缺血、脑缺血、缺血性心脏病、心绞痛、冠心病、创伤性脑损伤、精神病、焦虑、抑郁症、痴呆、记忆和注意力缺陷、阿尔茨海默病、痛经、嗜睡病、雷诺氏病、间歇性跛行、Sjorgren综合征、偏头痛、心律失常、高血压、失神发作、肌萎缩性肌肉营养不良、干口症、2型糖尿病、高胰岛素血症、早产、秃发、癌症和免疫抑制。
• Benzimidazole compounds, their preparation and use
  申请人：NEUROSEARCH A/S

  公开号：EP0604353A1

  公开（公告）日：1994-06-29

  The present invention discloses compounds of the formula or a pharmaceutically-acceptable addition salt thereof wherein R' and R'' independently of each other are hydrogen or alkyl, or R' and R'' together form a 3 to 6 membered alkylene chain; one of R¹ and R² is aryl which may be substituted one or more times with halogen, CF₃, CN, OH, alkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, amino, nitro, sulphamoyl, tetrazolyl, CO₂H, CO₂-alkyl and the other of R¹ and R² is hydrogen, halogen, alkoxy, amino or alkyl; and R⁴, R⁵, R⁶ and R⁷ independently of each other are hydrogen, halogen, amino, nitro, CN, OH, CF₃, alkyl or alkoxy; and n is 0 or 1; provided that neither of R¹ and R² is phenyl or substituted phenyl when n is 0. The compounds are useful as pharmaceuticals, for example, in the treatment of ischemia, anoxia, migraine and psychosis.

  本发明公开了如下式的化合物 或其药学上可接受的加成盐 其中 R'和 R''各自独立地为氢或烷基，或 R'和 R''共同形成 3 至 6 个成员的亚烷基链； R¹ 和 R² 中的一个为芳基，可被卤素、CF₃、CN、OH、烷基、环烷基、烯基、炔基、烷氧基、氨基、硝基、氨基磺酰基、四唑基、CO₂H、CO₂-烷基取代一次或多次，R¹ 和 R² 中的另一个为氢、卤素、烷氧基、氨基或烷基；以及 R⁴、R⁵、R⁶ 和 R⁷ 相互独立地为氢、卤素、氨基、硝基、CN、OH、CF₃、烷基或烷氧基；且 n 为 0 或 1；但当 n 为 0 时，R¹ 和 R² 均不是苯基或取代苯基。 这些化合物可用作药物，例如用于治疗缺血、缺氧、偏头痛和精神病。
• POTASSIUM CHANNEL BLOCKING AGENTS
  申请人：NEUROSEARCH A/S

  公开号：EP1091942A1

  公开（公告）日：2001-04-18
• US5441969A
  申请人：——

  公开号：US5441969A

  公开（公告）日：1995-08-15
• US6194447B1
  申请人：——

  公开号：US6194447B1

  公开（公告）日：2001-02-27